{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-003747","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.229691+00:00","generated_at":"2026-06-28T10:56:50.280664+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Design Therapeutics reports Q3 2021 net loss $11.3M; FA program on track for H1 2022","bullets":["Net loss $11.3M for Q3 2021; R&D expenses $8.5M, G&A $2.8M.","Cash, cash equivalents and securities total $393.7M as of Sept 30, 2021.","FA GeneTAC candidate on track for Phase 1 initiation in H1 2022; topline data expected in 2022.","DM1 program: preclinical data show near-complete resolution of foci; clinical start planned for 2023.","Company to present at Piper Healthcare Conference Nov 30 – Dec 2, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-003747","json":"https://secwatch.observer/filing/0000950170-21-003747.json","markdown":"https://secwatch.observer/filing/0000950170-21-003747.md","text":"https://secwatch.observer/filing/0000950170-21-003747.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000095017021003747/0000950170-21-003747-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000095017021003747/dsgn-20211109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:56:50.280664+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}